In Vivo Mir-146A Administration Reverses Pristane-induced Pulmonary Hemorrhage in C57BL/6 Mice (THER5P.836)

Dong Liang,Shiyu Zhou,Zheng Liu,Zhengyuan Shan,Philip Brohawn,Yihong Yao,John Harley,Nan Shen
DOI: https://doi.org/10.4049/jimmunol.192.supp.200.15
2014-01-01
Abstract:Abstract Purpose: MiR-146a as a lupus susceptibility gene plays a critical role in resolving acute inflammation. This study explored a therapeutic potential of miR-146a to treat Pristane-induced pulmonary hemorrhage in a murine model of lupus. Methods: The C57BL/6 (B6) mice were intravenously injected with PBS or miR-146a via lateral tail veins. The peripheral bloods from 3, 7 and 14 days post Pristane injection were evaluated by real time PCR or gene expression profile analysis. For comparison, the B6 mice were categorized into 3 groups, receiving respectively 3 consecutive injections of PBS (control group) or miR-146a either 3 days before (prevention group) or 7 days after (treatment group) a single intraperitoneal injection of Pristane. The pulmonary hemorrhage was histologically investigated by HE staining. Results: The injections of miR-146a mimic (agomir) increased its peripheral blood expression in both the prevention and treatment groups. HE staining showed that miR-146a administration reduced the prevalence of complete pulmonary hemorrhage from 56% in control group to 25% in treatment group and further to 0% in prevention group. Gene expression profile analysis showed that miR-146a treatment substantially suppressed multiple inflammatory signaling pathways. Conclusion: MiR-146a plays a suppressive role in the Pristane-induced pulmonary hemorrhage in B6 mice. Interference with miR-146a may constitute a useful therapeutic intervention for SLE patients with pulmonary hemorrhage.
What problem does this paper attempt to address?